minal

Right Now

Immunoprotein Diagnostic Testing Market To Reach $14.86 Billion By 2030

The global Immunoprotein Diagnostic testing market size is expected to reach USD 14.86 billion by 2030, registering a CAGR of 7.7% from 2025 to 2030, according to a new report by Grand View Research, Inc. This growth can be attributed to the rising incidence of chronic diseases.

According to American Heart Association’s 2017 statistics, nearly 790,000 people experience heart attack every year in the U.S. In addition, stroke is responsible for 1 in every 20 deaths in the U.S. Hence, WHO is also taking initiatives to reduce the risk of cardiovascular diseases. As a result of the aforementioned factors, the demand for Immunoprotein Diagnostic is expected to rise in order to facilitate rapid diagnosis.

According to WHO, nearly 1.69 million deaths due to lung cancer were registered in 2015 throughout the world. Hence, fast and accurate diagnosis of such chronic diseases has become important to reduce the high mortality rate. Immunoprotein diagnostic devices and reagents have proved to be highly effective in rapidly detecting chronic diseases.

Technological advancements in the field of Immunoprotein Diagnostic have led to introduction of novel products. For instance, LIAISON XL, manufactured by DiaSorin, is a fully automated chemiluminescence analyzer that facilitates complete sample processing. It also measures and evaluates testing samples, thereby, enhancing the efficiency and throughput of the system.

Immunoprotein Diagnostic Testing Market Report Highlights

The immunoglobulin diagnostic tests segment accounted for the largest revenue share of the market of 27.1% in 2024. These tests dominate the immunoprotein diagnostic testing market due to their critical role in diagnosing a wide range of conditions, including immune deficiencies, autoimmune disorders, and infectious diseases.
The infectious disease testing segment accounted for the largest revenue share of the market of 24.2% in 2024. Infectious disease testing is in high demand due to the increasing prevalence of infectious diseases, the need for early and accurate diagnosis, and the critical role these tests play in managing public health.
The enzyme-based immunoassay segment accounted for the largest revenue share of the market of 25.0% in 2024.
The retail sales segment accounted for the largest share of the market of 54.1% in 2024. This growth can be attributed to the increased accessibility and convenience for patients.
The hospitals and clinics segment accounted for the largest revenue share of the market of 44.7% in 2024. Hospitals and clinics serve a large number of patients daily, driving a high demand for diagnostic testing services.
North America immunoprotein diagnostic testing industry dominated and accounted for a 45.32% share in 2024. The market dominance can be attributed to technological advancements, the high prevalence of chronic diseases, and growing investments in research and development.

Curious about the Immunoprotein Diagnostic Testing Market? Download your FREE sample copy now and get a sneak peek into the latest insights and trends.

Immunoprotein Diagnostic Testing Market Segmentation

Grand View Research has segmented the Immunoprotein Diagnostic testing market on the basis of on test, application, technology, end-use, distribution channel, and region :

Immunoprotein Diagnostic Testing Test Outlook (Revenue, USD Million, 2018 - 2030)